Cabozantinib and Nivolumab for Carcinoid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04197310 |
|
Recruitment Status :
Completed
First Posted : December 13, 2019
Last Update Posted : February 14, 2024
|
Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Bristol-Myers Squibb
Exelixis
Information provided by (Responsible Party):
Kimberly Perez, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | December 27, 2023 |
| Actual Study Completion Date : | January 31, 2024 |